Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value.

Autor(es): Noto Yu-Ichi,Shibuya Kazumoto,Sato Yasunori,Kanai Kazuaki,Misawa Sonoko,Sawai Setsu,Mori Masahiro,Uchiyama Tomoyuki,Isose Sagiri,Nasu Saiko,Sekiguchi Yukari,Fujimaki Yumi,Kasai Takashi,Tokuda Takahiko,Nakagawa Masanori,Kuwabara Satoshi

Resumo: TAR DNA binding protein of 43 kDa (TDP-43) is likely to be the major pathogenetic protein in amyotrophic lateral sclerosis (ALS). A previous study has shown that levels of TDP-43 in CSF measured by an ELISA are significantly higher for ALS patients than for controls. The aim of this study was to investigate whether elevated CSF TDP-43 levels are specific to ALS, and are associated with clinical profiles in ALS patients. We measured CSF TDP-43 levels by the same ELISA in 27 ALS patients and 50 neurodegenerative or inflammatory disease controls such as Parkinson's disease, multiple sclerosis, and Guillain-Barré syndrome. Results showed that the CSF TDP-43 levels were increased only in ALS patients. Receiver operating characteristic (ROC) analyses showed a sensitivity of 59.3% and a specificity of 96.0%. We also found that lower CSF TDP-43 levels may be associated with shorter survival time. In conclusion, the CSF TDP-43 is a potential biomarker that supports a diagnosis of ALS. Moreover, among ALS patients, lower levels of CSF TDP-43 may reflect the accumulation of TDP-43 in the cortical and spinal motor neurons and thereby shorter survival time, although this should be confirmed in larger prospective studies.

Imprenta: Amyotrophic Lateral Sclerosis, v. 12, n. 2, p. 140-143, 2011

Identificador do objeto digital: 10.3109/17482968.2010.541263

Descritores: Guillain-Barre Syndrome - DNA ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Inflammation ; Guillain-Barre Syndrome - Public health

Data de publicação: 2011